DAT-5000A

DAT-5000A: sourced facts only. name: "DAT-5000A potently inhibited WRN in vitro activity both on ATPase and unwinding assays and showed good selectivity over BLM, another member of RecQ helicase." [DOI:10.1158/1538-7445.am2025-1755]; target: "DAT-5000A potently inhibited WRN in vitro activity both on ATPase and unwinding assays and showed good selectivity over BLM, another member of RecQ helicase." [DOI:10.1158/1538-7445.am2025-1755]; developer: "Danatlas Pharmaceuticals Co., Ltd., Beijing, China." [DOI:10.1158/1538-7445.am2025-1755]; modality: "Here we described the discovery of a novel non-covalent WRN inhibitor, DAT-5000A, with excellent potency and PK profile." [DOI:10.1158/1538-7445.am2025-1755]; stage: "DAT-5000A exhibited single-agent activity with tumor regression on MSI-H cell-line derived xenograft (CDX) tumor models, meanwhile DAT-5000A did not cause any abnormality on these mice." [DOI:10.1158/1538-7445.am2025-1755]